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Abstract
Theiler's murine encephalomyelitis virus (TMEV) is divided into two subgroups on the basis of their
different biological activities. GDVII subgroup strains produce fatal poliomyelitis in mice without
virus persistence or demyelination. In contrast, TO subgroup strains induce demyelinating disease
with virus persistence in the spinal cords of weanling mice. Two proteins, whose open reading
frames are located in the N-terminus of the polyprotein, recently have been reported to be
important for TMEV biological activities. One is leader (L) protein and is processed from the most
N-terminus of the polyprotein; its function is still unknown. Although the homology of capsid
proteins between DA (a representative strain of TO subgroup) and GDVII strains is over 94% at
the amino acid level, that of L shows only 85%. Therefore, L is thought to be a key protein for the
subgroup-specific biological activities of TMEV. Various studies have demonstrated that L plays
important roles in the escape of virus from host immune defenses in the early stage of infection.
The second protein is a 17–18 kDa protein, L*, which is synthesized out-of-frame with the
polyprotein. Only TO subgroup strains produce L* since GDVII subgroup strains have an ACG
rather than AUG at the initiation site and therefore do not synthesize L*. 'Loss and gain of function'
experiments demonstrate that L* is essential for virus growth in macrophages, a target cell for
TMEV persistence. L* also has been demonstrated to be necessary for TMEV persistence and
demyelination. Further analysis of L and L* will help elucidate the pathomechanism(s) of TMEV-
induced demyelinating disease.
Introduction
Theiler's murine encephalomyelitis virus (TMEV) belongs
to the genus Cardiovirus of the family Picornaviridae and is
classified into two subgroups of strains [1-4]. Although
the sequence identity between strains from these two sub-
groups is 90.4% at the nucleotide (nt) level and 95.7% at
the amino acid (AA) level [5,6], these subgroup strains
induce widely different biological activities. GDVII sub-
group strains produce acute fatal polioencephalomyelitis
in mice without virus persistence or demyelination. On
the other hand, TO subgroup strains cause a milder poli-
oencephalomyelitis followed by virus persistence and
demyelination. The pathological features of this demyeli-
nation are reminiscent of the human demyelinating dis-
ease, multiple sclerosis (MS) (Fig. 1) [1-4]. Although
several other viruses are known to induce demyelination
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[7], TMEV-induced demyelinating disease serves as an
excellent animal model for MS [1-4]. However, the precise
mechanisms of virus persistence and demyelination still
remain unknown.
Since infectious cDNAs were constructed from the late
1980s to the early 1990s [8-11], various studies using
recombinant viruses between GDVII and DA (or BeAn)
strains have been carried out to clarify the region respon-
sible for those biological activities. The studies have dem-
onstrated that capsid proteins, especially VP1 and VP2, are
important for virus persistence and demyelination [1,3].
In addition to these structural proteins, two proteins des-
ignated leader (L) and L* that are located in the N end of
the polyprotein (Fig. 2) also play a role in TMEV biologi-
cal activities [2,3,12].
The present review focuses on the roles of L and L* in reg-
ulating the biological activities of TMEV.
TMEV: properties and biological activities
The TMEV virion is an icosahedron approximately 28 nm
in diameter with no lipid-bilayer envelope. A single-
stranded RNA is packaged in the shell that consists of four
capsid proteins, VP1, VP2, VP3 and VP4 [13]. Neutralizing
epitopes have been identified [14-16], the nt and pre-
dicted AA sequence determined [5,9,17,18], and full-
length infectious cDNAs have been constructed [8-11]. In
addition, the three-dimensional structure was resolved by
means of X-ray crystallography in the early 1990s [19,20].
The RNA genome is positive sense and approximately
8,100 nt long. An open reading frame (ORF) between the
5' and 3' non-coding regions is translated into a long poly-
protein, which is then cleaved into L, P1, P2 and P3. The
5' terminus is covalently linked to VPg, which plays a role
in RNA replication. The 3' non-coding region has a poly
(A) tract. The coding regions for L and L* are located at the
most 5' terminus of the polyprotein coding region (Fig.
2). Details of this will be described later.
GDVII subgroup strains, typified by the GDVII strain, are
highly virulent and cause an acute fatal polioencephalo-
myelitis in mice after intracerebral and peripheral routes
of inoculation. After an incubation period of usually less
than 2 weeks, infected mice show circling, cachexia, and
ruffled hair with a progressive flaccid paralysis. Neither
virus persistence nor demyelination is observed in the few
surviving mice. Histopathological examination reveals
severe necrosis of neurons of the hippocampus, cortex,
and spinal cord anterior horn, with microgliosis, neu-
ronophagia, and inflammatory cell infiltration [1-4].
On the other hand, TO subgroup strains cause a biphasic
disease after intracerebral inoculation. The early disease,
which appears 1–2 weeks postinoculation (p.i.), has clin-
ical and pathological features that are similar to those
seen with the GDVII subgroup strains, but milder. Mice
recover from the early disease and then develop a chronic,
progressive white matter demyelinating disease 1–2
months p.i. Clinical signs include spastic paralysis, inac-
tivity and urinary incontinence. The demyelination
mainly affects the spinal cord, with an unexplained spar-
ing of the cerebellar hemispheric white matter. These
pathological findings are reminiscent of MS, that is,
inflammatory cell infiltration and loss of myelin in the
face of relative preservation of axons [1-4]. Therefore, this
demyelinating disease is considered to be an excellent ani-
mal model for MS, as noted above.
The target cell for DA persistence
Both subgroup strains of TMEV infect mainly neurons
during the acute stage of infection [1-4]. It is of interest
that DA viral antigen and RNA that are present in neurons
during the acute stage of infection disappear from neu-
rons in the chronic demyelinating stage, presumably
because these cells are cleared, perhaps by apoptosis. The
cellular localization of DA viral antigen and RNA in the
chronic demyelinating stage is somewhat controversial.
There are two proposals: viral persistence in oligodendro-
cytes and/or viral persistence in macrophages. Immunoe-
lectron microscopic study have shown viral antigen in
oligodendrocytes at 45 days p.i. or later. Based on this,
Rodriguez and coworkers proposed that a "gdying-back"
process might occur in virus-infected oligodendrocytes
[21,22], resulting in demyelination. In nude mice, demy-
elination occurs without evidence of myelin stripping by
macrophages, suggesting that the demyelination occurs
secondary to a lytic infection of oligodendrocytes [23].
Theiler's murine encephalomyelitis virus (TMEV)-induced  demyelination Figure 1
Theiler's murine encephalomyelitis virus (TMEV)-induced 
demyelination. Spinal cord from a female SJL/J mouse 6 
months postinoculation (p.i.) with DA strain of TMEV. 
Severe demyelination and scattered inflammatory cell infiltra-
tion are observed in the white matter (Klüver-Barrera stain, 
x40).Journal of Neuroinflammation 2006, 3:19 http://www.jneuroinflammation.com/content/3/1/19
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Also, in nude mice, electron microscopic studies have
demonstrated paracrystalline arrays of picornavirus in
degenerating glial cells, many of which were identified as
oligodendrocytes. A lytic infection of oligodendrocytes
has been proposed as a cause of the demyelination [24].
On the other hand, a number of studies have found that
the virus persists in macrophages. Using ultrastructural
immnohistochemical techniques, researchers have
observed viral inclusions in macrophages in and around
demyelinating lesions [25]. Two-color immunofluores-
cent staining has shown that viral antigen is predomi-
nantly within macrophages infiltrating demyelinating
lesions [26]. Infectious virus can be recovered from infil-
trating mononuclear cells isolated directly from the cen-
tral nervous system (CNS) [27]. Cultured primary brain
macrophages can be efficiently infected with the DA strain
without the induction of a significant cytopathic effect
[28]. The importance of macrophages in late demyelinat-
ing disease is further emphasized by the observation that
depletion of blood-borne macrophages by dichlorometh-
ylene diphosphonate prevents virus persistence in mice
infected with the DA strain [29]. From these data, it
appears likely that macrophages are the major cells con-
taining persistent viral genome. Therefore, the mecha-
nism by which DA survives in macrophages may clarify
DA persistence.
L and picornaviruses
The aphthoviruses and caridioviruses are the only mem-
bers of the Picornaviridae family that contains an L coding
region at the most 5' terminus of the ORF [13]. In the case
of foot-and-mouth disease virus (FMDV), an aphthovirus,
L has two proteolytic functions. One is autocatalytic cleav-
age from the viral polyprotein [30,31], and the second is
cleavage of the p220 component of the cap-binding pro-
tein complex [32], resulting in the shut off of host protein
synthesis. On the other hand, the function of L of the car-
dioviruses is not well defined.
L has been implicated in other functions of picornavi-
ruses. FMDV L is involved in inhibiting phosphorylation
of eukaryotic initiation factor 2 by double-strand RNA-
dependent protein kinase [33]. L of cardioviruses inhibits
the expression of alpha/beta interferon (IFN α/β) (see
later discussion), which is a critical tool to inhibit viral
spread. L of mengovirus, which also belongs to the genus
Cardiovirus, has been reported to inhibit the iron/ferritin-
mediated activation of NFκB [34]. The functions of L of
TMEV genome and two different initiation sites Figure 2
TMEV genome and two different initiation sites. All the TMEVs have an authentic initiation site at nucleotide (nt) 1066, from 
which the polyprotein is translated followed by cleavage into L, P1, P2 and P3. DA subgroup strains synthesize a small 17–18 
kDa protein, L*, from an alternative, out-of-frame, initiation site, which is located at nt 1079. In contrast, GDVII subgroup 
strains or DAL*-1 virus do not synthesize L* since the L* initiating AUG is replaced with ACG.
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TMEV and the other cardioviruses remain incompletely
clarified.
The properties of TMEV L
TMEV L, which is processed from the most N-terminus of
the polyprotein, consists of 76 amino acids [17,18] (Fig.
2). The release of L occurs rapidly. However, it lacks auto-
catalytic activity [35].
Although the identity of capsid proteins between DA and
GDVII strains is over 94% at the AA level, that of L shows
only 85% identity [5,6]; the low identity of the AA
sequence of L between both TMEV subgroups suggests
that L may contribute to the determination of the DA sub-
group-specific biological activities, such as attenuated
neurovirulence, viral persistence and demyelination. In
addition, the identity of TMEV L with L of EMCV, which
belongs to the same cardiovirus genus, is ~35 % although
that of the entire coding region is about 60%. TMEV L
contains a zinc-binding motif Cys-His-Cys-Cys that, inter-
estingly, is present in L from all the cardioviruses [6,36].
Our unpublished data demonstrate that L is synthesized
with the same kinetics as capsid proteins and is not incor-
porated into the virion. L is synthesized in the cytoplasm
of host cells and, in part, transferred into the nucleus [37].
The data suggest that L may function through its interac-
tions with cellular protein(s).
The biological activities of TMEV L
A mutant DA or GDVII virus with a deletion of L causes
poor growth in the L929 mouse fibroblast cell line that
produces IFN α/β, but not in BHK-21 cells producing no
IFN α/β [38,39]. Since L of DA strain has been reported to
inhibit the transcription of IFN α/β [36,40], the replica-
tion of virus is suppressed under pressure of IFN α/β. L
prevents transcription of IFN α/β because of its interfer-
ence with the nuclear localization of IFN regulatory factor
3 (IRF-3), a transcription factor required for the expres-
sion of IFN α/β [37]. The zinc-binding motif within L
directly binds zinc ions and is a key factor in the inhibi-
tion of IFN α/β expression [36,37,40,41].
The importance of IFN α/β  in the animal's host cell
defense from TMEV infection has been demonstrated in
TMEV infections of IFN α/β receptor-deficient mice [42].
These mice die of overwhelming encephalomyelitis fol-
lowing intracerebral inoculation with DA strain because
of enhanced virus replication. Similarly, DA virus with a
mutation in the zinc-binding motif of L is cleared from
the CNS since the mutation induces the transcription of
IFN α/β, resulting in production of IFN α/β [36].
The inhibition of IFN α/β by L, however, is not enough to
allow TMEV to escape all host defense mechanisms.
Indeed, DA strain is cleared after the first phase of disease
in genetically resistant C57BL/6 mice in which L is
expressed. Disruption of β2-microglobulin gene in resist-
ant mice, which fail to express class I MHC molecules and
therefore lack CD8+ T lymphocytes, abrogates resistance
to the DA strain, allowing the virus to persist [43]. This
report suggests that class I-restricted CD8+ T lymphocytes
are important for persistent infection, in addition to inhi-
bition of IFN α/β by L.
The properties of L*
During an investigation of polyprotein processing, Roos
et al identified a small 17–18 kDa protein that is synthe-
sized in vitro in rabbit reticulocyte lysates programmed
from in vitro-derived transcripts of full-length clones of
DA strain cDNA [35]. DA subgroup strains have an alter-
native translation initiation site at nt 1079, in addition to
the authentic initiation site for the polyprotein at nt 1066
[44] (Fig. 2). This alternative initiation site is out-of-frame
with the polyprotein and is used to translate the 17–18
kDa protein, designated L*. The synthesis of L* is TO sub-
group-specific because this alternative initiation site is not
present in GDVII subgroup strains (where the L* AUG is
substituted by an ACG) (Fig. 2) [6,44]. Therefore, this DA
subgroup-specific out-of-frame protein is thought to play
an important role in characterizing the different biologi-
cal activities of TMEV subgroups, especially viral persist-
ence and demyelination.
There were initial difficulties in generating an anti-L* anti-
body, perhaps related to a relative lack of antigenicity or
to extreme hydrophobicity resulting in solubility prob-
lems. These difficulties were overcome with the produc-
tion of a rabbit polyclonal antibody against synthetic
peptides corresponding to amino acid residues 70–88
(the computer-predicted antigenic site) [45,46]. Studies
employing this antibody have demonstrated that L* is
synthesized with kinetics similar to that of other viral pro-
teins, although in a lesser amount. After synthesis, L*
remains stable in the cytoplasm and is not incorporated
into virions. Immunofluorescent staining and immunob-
lotting of microtubule preparations have demonstrated
that L* is associated with microtubules. Experiments
employing transient expression of L* have suggested that
the 5' one third of the L* coding region is responsible for
this association [46].
The role of L* in virus growth in macrophages
We examined the growth patterns of DA (which persists in
the CNS) and GDVII (which does not persist) strains in
J774-1 cells, a representative mouse macrophage cell line,
since macrophages are the target cells for virus persistence,
as described above [25-29]. The growth curves clearly
demonstrated that DA strain grows well in J774-1 cells,
while GDVII strain does not. On the other hand, bothJournal of Neuroinflammation 2006, 3:19 http://www.jneuroinflammation.com/content/3/1/19
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strains grew well equally in BHK-21 cells [47]. These
results are of interest since virus growth is necessary for the
maintenance of the viral genome, which is essential for
virus persistence [48]. TMEV subgroup-specific virus
growth was studied in various other cell lines including
neural cells. The results demonstrated that enhanced DA
growth compared to GDVII is only observed in macro-
phage cell lines. Therefore, the TMEV subgroup-specific
virus growth is also host cell-dependent [49].
The role of L* in TMEV subgroup-specific virus growth
was further studied in a 'loss of function' experiment using
a mutant virus, DAL*-1, which has an ACG rather than
AUG at the initiation site of L* coding region, and there-
fore does not synthesize L*. Takata et al found that the
DAL*-1 virus failed to grow in J774-1 cells, whereas the
virus grew well in BHK-21 cells [50]. In addition, DAL*-1
virus failed to grow in other macrophage cell lines, sug-
gesting that L* plays an important role in host cell-
dependent subgroup-specific infection [49].
In order to carry out a 'gain of function' experiment to fur-
ther confirm the role of L* in host cell-dependent sub-
group-specific virus growth, Obuchi et al constructed a
recombinant virus, DANCL*/GD, which has DA 5' non-
coding and L* coding regions in the background of GDVII
(with synthesis of L*). DANCL*/GD virus had enhanced
growth activity in J774-1 cells compared to GDVII, sug-
gesting that L* is important for the subgroup-specific virus
growth in macrophages [45]. However, a pitfall of L* in
studies such as these involving L* is that the sequence of
L* overlaps with that of polyprotein (L and a part of P1).
Therefore, it is impossible to evaluate the role of L* with-
out affecting the nt sequence of the corresponding coding
region of the polyprotein. In order to overcome this situ-
ation, we recently established an L*-expressing J774-1 cell
line. GDVII and DAL*-1 viruses do not grow in control
cells, which do not express L*, whereas virus growth is
enhanced in L*-expressing cells [51]. van Eyll et al also
have shown that L* ORF is required for virus growth in
macrophage cell lines [52]. Therefore, L* is essential for
host cell-dependent subgroup-specific virus growth,
which is likely to play an important role in TMEV patho-
genesis.
L* and apoptosis of macrophages
TMEV is reported to induce apoptosis in vitro and in vivo.
Tsunoda et al detected the apoptosis in vivo and suggested
that the apoptosis of neurons may be responsible for the
fatal outcome of GDVII infection [53]. Apoptosis has also
been found during the chronic stage of DA infection [54].
Of interest, the majority of apoptotic cells (CD3+ T cells)
were uninfected, suggesting an activation-induced cell
death.
The role of L* in apoptosis is studied in both 'loss of func-
tion' and 'gain of function' experiments. In a 'loss of func-
tion' experiment, a macrophage cell line, P388D1, was
infected by wild type DA (which synthesizes L*) as well as
DAL*-1 and GDVII viruses (neither of which synthesizes
L*). DAL*-1 and GDVII viruses induced DNA laddering
12 hrs p.i., however, wild type DA did not. TUNEL-stain-
ing demonstrated that DAL*-1 and GDVII viruses caused
apoptosis in 38% and 43% of P388D1 cells, respectively,
while only 6% of DA-infected cells were apoptotic. These
studies suggest that L* has an anti-apoptotic activity in
macrophage cells [55]. In contrast to these findings, TMEV
infection of microglia does not induce apoptosis [56]. The
differing results may relate to special properties of micro-
glia that are distinct from those of circulating macro-
phages.
Himeda et al established L*-expressing P388D1 cells to
confirm the anti-apoptotic activity of L* in a 'gain of func-
tion' experiment [57]. DAL*-1 virus induced prominent
DNA laddering in control cells that do not express L*, but
failed to do so in L*-expressing P388D1 cells. The activity
of caspase-3 was raised in the control cells and was inhib-
ited by a caspase family inhibitor, Z-VAD-FMK, whereas
caspase activity was significantly decreased in L*-express-
ing cells. The authors speculate that the major apoptotic
pathway following TMEV infection may be a death recep-
tor-mediated pathway since no cytochrome c release was
detected.
The role of L* in virus persistence and demyelination
A challenging issue that remains is whether L* plays a role
in virus persistence and demyelination. An initial ques-
tion that required answering is whether L* is expressed in
vivo. Asakura et al first demonstrated the expression of L*
in vivo by means of immunoprecipitation and immunob-
lotting studies using anti-L* antibody [58]. These studies
also localized L* in the mouse CNS during the acute stage
of infection. L* was identified in neurons and colocalized
with capsid protein, VP1.
L* was found to play an important role in virus persist-
ence and demyelination by employing a 'loss of function'
experiment. DAL*-1 virus produces an early acute poli-
oencephalomyelitis similar to the parental DA, however,
the viral RNA genome is no longer detected in the spinal
cord of mice 6 weeks p.i. [55]. In addition, there is mini-
mal if any evidence of demyelination or inflammation in
the spinal cord [59]. L* appears to inhibit the generation
of H-2K-restricted TMEV-specific cytotoxic T cells, there-
fore permitting a persistent infection to occur in suscepti-
ble mouse strains [60]. However, it is also reported that
wild type-DA (which expresses L*) induces H-2K-
restricted TMEV-specific cytotoxic T cells [61], In addition,
the above findings regarding L* were also called intoJournal of Neuroinflammation 2006, 3:19 http://www.jneuroinflammation.com/content/3/1/19
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question by Michiels and colleagues because the absence
of the L* AUG initiation codon in a mutant DAL*-1 virus
generated from a different DA infectious clone had only a
weak influence on virus persistence [62]. The discrepancy
is due to one nt sequence of the two viruses (Roos, R., per-
sonal communication). Further studies by van Eyll et al
[52] using DA virus mutants with a stop codon in the L*
reading frame (leading to a truncated L*) confirmed the
key role of L* in virus persistence and demyelination.
Yamasaki et al. reported a utilization of the L* translation
initiation vs. the polyprotein's AUG [63]. These investiga-
tors proposed that L* (rather than the polyprotein) is
preferentially synthesized in certain CNS cells (e.g. micro-
glial cells) following infection with DA subgroup strains.
The production of only small amounts of capsid protein
in certain cells would foster virus persistence and lead to
restricted expression of the virus in the chronic stage.
The above data indicate that L* is a key determinant of
TMEV persistence, subsequently leading to an inflamma-
tory demyelination in the CNS, similar to that in MS.
However, all the in vivo data that have been obtained to
date are from 'loss of function' experiments. Additional
data through by 'gain of function' experiments, such as
those involving L*-expressing transgenic mice, would be
valuable in order to confirm the role of L* protein in vivo.
From the above data regarding L and L*, it is speculated
that DA strain could escape from host immune defense(s)
through the inhibition of IFN α/β by L in the early stage
of infection. DA that had escaped from early immune
attack could then maintain its genome in macrophages
with the aid of L* in the chronic stage of infection. The
presence of TMEV genome in macrophages could trigger a
cascade of immune system, leading to immune-mediated
demyelination.
Conclusion
Both DA and GDVII subgroup strains of TMEV synthesize
L, which consists of 76 AA and is processed from the most
N-terminus of the polyprotein. L contains a zinc-binding
motif, Cys-His-Cys-Cys, which is conserved among all car-
dioviruses and directly binds to zinc ions. L prevents tran-
scription of IFN α/β through interference of the nuclear
localization of IRF-3, a transcription factor important for
the expression of IFN α/β.
DA subgroup strains synthesize L*, which is out of frame
with the polyprotein. GDVII subgroup strains have an
ACG rather than AUG corresponding to the initiation
codon of L*, resulting in no synthesis of L*. A 'loss of
function' experiment using mutant DA virus that fails to
synthesize L*, as well as a 'gain of function' experiment
using an L*-expressing macrophage cell line, demon-
strated that L* has anti-apoptotic activity and is required
for virus growth in macrophages. In vivo experiments
using mutant DA virus, in which L or L* is not synthe-
sized, also demonstrated that these are key proteins regu-
lating the DA subgroup-specific biological activities, i.e.,
virus persistence and demyelination. Further studies clar-
ifying the roles of L and L* will elucidate the pathomech-
anism(s) of TMEV-induced demyelinating disease, and
may also provide insights into our understanding for MS.
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